You are here: Industry Insights > msd

News List

MSD's Keytruda bags approval for new skin cancer indication pharmatimes
June 29, 2020
MSD's Keytruda (pembrolizumab) has been cleared for use in the US as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) not curable by surgery or radiation.
MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes trial pharmatimes
June 22, 2020
MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety of their diabetes drug Steglatro (ertugliflozin).
MSD's Keytruda misses advanced bladder cancer goal pharmatimes
June 16, 2020
MSD's Keytruda (pembrolizumab) has failed to hit key goals in a trial assessing its potential as a first-line treatment for bladder cancer.
US expands scope of MSD's Gardasil pharmatimes
June 16, 2020
MSD has bagged US approval for an expanded indication for Gardasil for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
MSD's Keytruda doubles PFS in bowel cancer subset pharmatimes
May 29, 2020
MSD's immunotherapy Keytruda (pembrolizumab) more than doubled progression free survival in patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.
US nod for Lynparza in HRD-positive advanced ovarian cancer pharmatimes
May 12, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.
FDA approves AstraZeneca’s Koselugo to treat rare genetic disorder pharmaceutical-technology
April 14, 2020
AstraZeneca and MSD (Merck) have received the US Food and Drug Administration (FDA) approval for Koselugo (selumetinib) to treat a rare genetic condition called neurofibromatosis type 1 (NF1).
Higher dose of gefapixant hits endpoints in chronic cough trial pharmatimes
March 19, 2020
MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough.
Keytruda improves PFS in classical Hodgkin lymphoma pharmatimes
March 06, 2020
MSD has announced more Keytruda (pembrolizumab) results, this time for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer worldpharmanews
January 16, 2020
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page